drugset / Trial / NCT01273662
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Phase 2
Completed
45 enrolled
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study of axitinib as the second-line on the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study is a proof-of-concept study to see if axitinib has any anti-tumor effect in HCC. The primary endpoint is disease stabilization that lasts for at least 8 weeks without progression of tumor-related symptoms.
Timeline
- Start
- 2011-04
- Primary completion
- 2016-03
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |